Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
957.76
+5.36 (0.56%)
At close: Nov 17, 2026, 4:00 PM EST
965.00
+7.24 (0.76%)
After-hours: Nov 17, 2026, 6:14 PM EST

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 28 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $990.81. The average 1-year stock price forecast is 3.45% higher than the current stock price, while the lowest is $812 (-15.22%) and the highest is $1,175 (+22.68%).

Price Target: $990.81 (+3.45%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$812$990.81$1,000$1,175
Change-15.22%+3.45%+4.41%+22.68%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy161414131515
Buy544444
Hold8109989
Sell001110
Strong Sell000000
Total292828272828

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Barclays
Barclays
Buy
Maintains
$917 → $1,075
BuyMaintains$917 → $1,075+12.24%Nov 17, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$1,175
BuyMaintains$1,175+22.68%Nov 11, 2026
Citi
Citi
Hold
Maintains
$825
HoldMaintains$825-13.86%Nov 11, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$1,030
BuyMaintains$1,030+7.54%Nov 11, 2026
BMO Capital
BMO Capital
Buy
Maintains
$920 → $1,050
BuyMaintains$920 → $1,050+9.63%Nov 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
18.81B
from 14.34B
Increased by 31.18%
Revenue Next Year
20.17B
from 18.81B
Increased by 7.19%
EPS This Year
69.09
from 44.31
Increased by 55.92%
EPS Next Year
71.10
from 69.09
Increased by 2.91%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
16.07B12.17B13.12B14.20B14.34B18.81B
Revenue Growth
89.14%-24.26%7.76%8.27%0.99%31.18%
Operating Income
8.99B4.99B4.23B4.15B3.70B8.04B
Net Income
8.08B4.34B3.95B4.41B4.50B6.43B
EPS
----44.3169.09
EPS Growth
-----2.87%55.92%
Forward PE
11.0017.2919.3615.1917.1213.86
Dividend / Share
----3.523.78
Free Cash Flow
----4.08B7.08B
No. Analysts
-----25
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High19.5B
Avg18.8B
Low17.8B

Revenue Growth

Revenue Growth202620272028
High
35.9%
Avg
31.2%
Low
24.2%

EPS Forecast

EPS202620272028
High74.53
Avg69.09
Low61.35

EPS Growth

EPS Growth202620272028
High
68.2%
Avg
55.9%
Low
38.5%